APPROVED_FOR_MARKETINGNCT05183802

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

Studying Bardet-Biedl syndrome

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Rhythm Pharmaceuticals, Inc.
Principal Investigator: Linda Shapiro, M.D., Ph.D.
Chief Medical Officer, Rhythm Pharmaceuticals
Intervention: Setmelanotide, administered subcutaneously [SC], once daily.(drug)
Eligibility: 6 years · All sexes

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05183802 on ClinicalTrials.gov

Other trials for Bardet-Biedl syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06239064
Early Genetic Identification of Obesity
Rolfs Consulting und Verwaltungs-GmbH (RCV)
RECRUITINGNCT02329210
Clinical Registry Investigating Bardet-Biedl Syndrome
Marshfield Clinic Research Foundation

See all trials for Bardet-Biedl syndrome →

← Back to all trials